FindTrial
Sign In

Influenza VLP study

Immunological response to Influenza hemagglutinin and neuraminidase gene and development of Influenza VLPs

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/02/031006
Enrollment
320
Registered
2021-02-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J09X- Influenza due to identified novelinfluenza A virus

Interventions

None listed

Sponsors

Manipal Institute of Virology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients positive for Influenza A(H1N1) and Influenza A(H3N2)

Exclusion criteria

Exclusion criteria: Patients negative for Influenza A(H1N1) and Influenza A(H3N2)

Design outcomes

Primary

MeasureTime frame
ï?? Developing a VLP expressing both HA and NA antigens of Influenza A (H1N1) and Influenza A (H3N2) viruses will be a novel study. ï?? No data is available in India on immunological responses to influenza virus and effect of pre-existing antibodies. This study will form a platform for future immune response studies. ï?? The VLPs successfully developed as part of this study can be patented. Timepoint: 3 Years—

Secondary

MeasureTime frame
ï?? No data is available in India on immunological responses to influenza virus and effect of pre-existing antibodies. This study will form a platform for future immune response studies.Timepoint: 3 Years—

Countries

India

Contacts

Public ContactAnup Jayaram

Manipal Institute of Virology

anupjayaram83@gmail.com9482406560

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026